EMA Authorised: Repaglinide Teva (repaglinide) — Teva Pharma B.V.

View source ↗

Summary

The EMA has authorised Repaglinide Teva (repaglinide) for the treatment of type 2 diabetes mellitus, with Teva Pharma B.V. as the marketing authorisation holder…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Repaglinide Teva (repaglinide)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Teva Pharma B.V.. Decision date: 11/02/2025